ArticleBiomaterials2015
Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.
Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.Pharmaceutical research · 2022Pooled it
- Nanoparticle approaches for hepatitis therapy and clinical translation.Discover nano · 2026Review
- Click Chemistry for Biofunctional Polymers: From Observing to Steering Cell Behavior.Chemical reviews · 2024Review
- Magnetic Relaxation Switching Assay Using IFNα-2b-Conjugated Superparamagnetic Nanoparticles for Anti-Interferon Antibody Detection.Biosensors · 2023Article
- Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening.Interdisciplinary sciences, computational life sciences · 2022Article
- Nanotechnology for virus treatment.Nano today · 2021Review
- Inorganic and Polymeric Nanoparticles for Human Viral and Bacterial Infections Prevention and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.Acta biomaterialia · 2020Article
- Recent trends in click chemistry as a promising technology for virus-related research.Virus research · 2018Review
- Cell membrane-derived nanomaterials for biomedical applications.Biomaterials · 2017Review
- Hepatitis C virus management: potential impact of nanotechnology.Virology journal · 2017Review
- Role of apoptotic hepatocytes in HCV dissemination: regulation by acetaldehyde.American journal of physiology. Gastrointestinal and liver physiology · 2016Article
- Biomimetic strategies for targeted nanoparticle delivery.Bioengineering & translational medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Great success in HCV therapy was achieved by the development of direct-acting antivirals (DAA). However, the unsolved issues such as high cost and genotype dependency drive us to pursue additional therapeutic agents to be used instead or in combination with DAA. The cationic peptide p41 is one of such candidates displaying submicromolar anti-HCV potency. By electrostatic coupling of p41 with anionic poly(amino acid)-based block copolymers, antiviral peptide nanocomplexes (APN) platform was developed to improve peptide stability and to reduce cytotoxicity associated with positive charge. Herein, we developed a facile method to prepare galactosylated Gal-APN and tested their feasibility as liver-specific delivery system. In vitro, Gal-APN displayed specific internalization in hepatoma cell lines. Even though liver-targeted and non-targeted APN displayed comparable antiviral activity, Gal-APN offered prominent advantages to prevent HCV association with lipid droplets and suppress intracellular expression of HCV proteins. Moreover, in vivo preferential liver accumulation of Gal-APN was revealed in the biodistribution study. Altogether, this work illustrates the potential of Gal-APN as a novel liver-targeted therapy against HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.